Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Melanoma 2Small Cell Lung Carcinoma 1Sarcoma 1Parathyroid Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

Etoposide 155Carboplatin 145Cisplatin 106Topotecan 76durvalumab 52atezolizumab 50Irinotecan 45pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 31PM 01183 24Drug Therapy 24anlotinib 23Gemcitabine 21apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Magnetic Resonance Spectroscopy 13Bevacizumab 13rovalpituzumab tesirine 11amrubicin 11Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Dacarbazine × Thoracic × Clear all
NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Virginia Commonwealth University

Phase 1 Completed
17 enrolled
DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡